MASCC Febrile Neutropenia Risk Index
Identifies patients with febrile neutropenia at low risk of complications.
When to use
Adults with febrile neutropenia, to support the decision between outpatient treatment and admission.
Pearls and pitfalls
- The score gives more weight to absence of hypotension, absence of COPD and solid tumor.
- A value of 21 or more defines low risk in the original study.
- Low risk does not guarantee safety; assess social support, access and ability to return.
- The score does not replace clinical assessment or the decision on empirical antibiotics.
Fill in the fields to see the result.
Formula
Add symptoms (5, 3 or 0), no hypotension (5), no COPD (4), solid tumor or no prior fungus (4), no dehydration (3), outpatient onset (3) and age below 60 (2).
Evidence
Multinational index derived to identify febrile neutropenic patients at low risk of serious complications.
References
- Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051. doi:10.1200/JCO.2000.18.16.3038
Frequently asked questions
What is MASCC Febrile Neutropenia Risk Index?
Identifies patients with febrile neutropenia at low risk of complications. Adults with febrile neutropenia, to support the decision between outpatient treatment and admission.
How is the result calculated?
Add symptoms (5, 3 or 0), no hypotension (5), no COPD (4), solid tumor or no prior fungus (4), no dehydration (3), outpatient onset (3) and age below 60 (2).
How should the result be interpreted?
Multinational index derived to identify febrile neutropenic patients at low risk of serious complications.
What are the sources?
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051.